hubXchange’s Post

FluoSphera is a patent-protected technology platform developing a unique set of disruptive technologies mimicking the clinical response to drugs under systemic conditions to accurately predict drug safety and efficacy. Such high-throughput systemic assays reliably identify the most promising lead compounds early during drug discovery to decrease drug development failure in the clinic, thus increasing the chance for the patients to get access to the best therapeutics while reducing animal experimentation. Meet FluoSphera @ #Sachs_ELSF More Info @ https://lnkd.in/dQWhKYkV #ELSF2024 #LifeSciences #Biotech #BioPharma #Partnering #Investment #Startups #RisingStars #Oncology #Neurology #Genomics #Immunotherapy #CNS #Autoimmune #Cardiovascular #BiotechIndustry #BioTechInvestment #Innovation #InvestmentForum #SachsSpringLifeSciencesWeek #SSLSW

🎊Delighted to provide a preview of Translational Research (Track 2) at our upcoming Immuno-Oncology Xchange event in Boston! 📌Secure your spot and register for free: https://bit.ly/4clU9OU Don't miss this opportunity to explore more into translational research in immuno-oncology! Connect with industry experts and gain valuable insights! ⭐ Here's the highlights: 📑 Translational immune modulating strategies to develop effective therapeutics to enhance immune cell engagement and access to tumors. 🗣️ Munir Mosaheb, Head of Translational Biology, Senda Biosciences 📑 Developing immune cells with better in vivo persistence. 🗣️ Christopher Dupont, Associate Director (Clinical Translational Lead), Adaptimmune 💊 Only available for Senior Scientists and above, from Bio and Pharma companies with a drug pipeline. 💊 🤝 Our Partners ‣ Biorasi ‣ Enable Medicine ‣ Oncocyte Corporation ‣ Flagship Biosciences, Inc. ‣ WuXi Advanced Therapies ‣ CDI Labs ‣ Nona Biosciences * Agenda subject to change. #TranslationalResearch #ImmunoOncology #CancerResearch #Therapeutics #TumorMicroenvironment #Immunotherapy #ImmuneSystem #FlowCytometry #TumorImmunity #ClinicalResearch #CancerTreatment #Immunophenotyping #CellSorting #TumorAntigens #TherapeuticDevelopment #TumorHeterogeneity #ImmuneModulation #ClinicalTrials #BiomedicalResearch #DrugDevelopment #hubXchange #Xchanges #Roundtable #FreePass #RegisterNow #ComplimenatryPass

According to the World Health Organization, AI-powered drug discovery platforms have slashed the time and cost of bringing new cancer drugs to market by up to 50%! This remarkable advancement is paving the way for the development of more targeted and effective therapies. By harnessing the power of artificial intelligence, researchers can sift through vast amounts of data and identify promising drug candidates with unprecedented speed and accuracy. This accelerated drug discovery process allows for quicker translation of scientific discoveries into life-saving treatments for cancer patients. #AIinOncology #PrecisionMedicine #CancerResearch #DrugDiscovery #ArtificialIntelligence #MedicalInnovation #HealthTech #PersonalizedMedicine #InnovationInHealthcare #CancerTreatment #HealthcareAI #ClinicalTrials #DigitalHealth #Biotechnology #OncologyResearch

Unveiling Growth Opportunities in the Global #OrphanDrug Industry ⚕️ Amidst the landscape of #rarediseases, the quest for innovative treatments intensifies, fueled by a convergence of advancements in #precisionmedicine, #informatics, and #oncology. Frost & Sullivan's latest analysis uncovers how emerging technologies like precision oncology and gene-editing techniques are reshaping the orphan drug (OD) industry. 🔗Dive into our comprehensive perspectives to seize the #growthopportunities in this dynamic sector 👉https://hubs.la/Q02sxhx-0 Robin Joffe | Nitin Naik | Nimisha Iyer | Sowmya Srinath | Unmesh Lal | Sudhakar Mishra | Aarti Natu Chitale | Surbhi Gupta | Sherin George | Shylesh Narayanan

Unlocking the Potential of the Biomarkers Market by Application 📥 Download the PDF: https://lnkd.in/ghacfmXp The biomarkers market is at the forefront of transforming healthcare, with applications spanning diagnostics, drug development, and personalized medicine. As we project remarkable growth—from $57.7 billion in 2024 to $93.8 billion by 2029, driven by a CAGR of 10.2%—it's essential to explore the diverse applications that are propelling this market forward. Key applications include: - Disease Diagnosis: Enhancing early detection, especially for cancer. - Drug Development: Improving efficacy and reducing costs. - Personalized Medicine: Tailoring treatments to individual patients. - Prognostic Indicators: Offering insights into disease progression. - Therapeutic Monitoring: Adjusting treatments based on patient response. While the growth of the biomarkers market is promising, challenges such as disease complexity, heterogeneity, and data integration need to be addressed to fully realize its potential. Key players like Roche, Merck, and Thermo Fisher Scientific are leading the charge, particularly in North America, which holds a significant market share due to its robust research and clinical trial infrastructure. Recent developments, including strategic partnerships for advanced diagnostic tools and innovative antibody launches aimed at detecting conditions like cancer and Alzheimer’s disease, underscore the dynamic nature of this market. Other Companies that are Operating in this Market Globally: Citoxlab, a Charles River Company BioSerenity Idoven Owlstone Medical Nucleix Ltd. Pelago Bioscience AB Bioneer A/S Rockley Photonics MaaT Pharma Fujirebio K2 Medical Research BioArctic Indivi TECHLAB, Inc. Brainomix Optics11 Life Amsterdam UMC - Cancer Center Amsterdam Aiforia Technologies C3i Transpharmation Ltd. Forus Health Promptly Health AVESTHAGEN LIMITED TATAA Biocenter #Biomarkers #PersonalizedMedicine #Oncology #HealthcareInnovation #DrugDevelopment #Diagnostics #PrecisionMedicine

If you need help with your #drugdiscovery and #drugdevelopment programs you might want to check out some of our latest innovations. Have a look at this post by Iván from Discovery | Charles River

⚗️ Don’t miss this opportunity to deepen your understanding of neuroinflammation models in drug discovery! 🔬 Join Stefan Ebner-Benke at his must-attend session "A Guide through Preclinical Drug Testing Systems for Neuroinflammation" 🧬 Neuroinflammation is a key feature of various CNS diseases, making accurate preclinical models essential for drug development. This presentation will guide you through the preclinical models of neuroinflammation used at Scantox Discovery. From early screens in microglia to advanced ex vivo models (like organotypic brain slices and brain organoids) and in vivo models of inflammatory phenotypes, this session covers it all. Learn about key concepts, opportunities, and potential pitfalls critical for selecting the right models for drug discovery. 📅 Date: June 24th, 2024 🕒 Time: 15:00 – 15:30 📍 Location: Hilton Woburn Hotel, Boston 🗣️ Stefan leads the study coordination at Scantox Neuro GmbH, overseeing operations and study execution in preclinical research. With a background in molecular biology and microbiology from the University of Graz and a PhD from the Max Perutz Labs (University of Vienna), Stefan has a deep academic interest in neurodegenerative diseases and immunity. He also holds an Executive Management MBA from California Lutheran University and has extensive experience as an innovation consultant. Stefan leverages his expertise to drive scientific excellence and customer success at Scantox Neuro GmbH. ✍🏼 Register now for your COMPLIMENTARY pass! https://bit.ly/3TIPjE1 ✍🏼 * Agenda subject to change 💊 Only available for Senior Scientists and above, from Bio and Pharma companies with a drug pipeline. 💊 #Neuroinflammation #DrugDiscovery #PreclinicalResearch #ScantoxDiscovery #Biotech #CNSDiseases #ScientificExcellence #Innovation #Healthcare #hubXchange #Roundtable #FreePass #RegisterNow #ComplimentaryPass

IAMA stands at the forefront of drug discovery, revolutionizing the treatment landscape for complex CNS diseases. Pioneering a groundbreaking platform targeting chloride cotransporters, IAMA’s lead compound, IAMA-6, selectively targets NKCC1, offering an innovative approach. Fueled by compelling preclinical evidence and backed by €8M in funding from prestigious entities, including Telethon and Angelini, IAMA secured an additional €12M round in 2022, led by Claris Ventures and CDP Venture Capital.  In under two years, the company advanced IAMA-6 to Phase 1 clinical trial in healthy volunteers, marking a swift trajectory toward clinical development in patients. With a robust pipeline addressing significant unmet needs, IAMA is strategically positioned for substantial impact in both rare and broad market applications. Leveraging deep expertise, the company is committed to developing treatments for patients battling neurological diseases without a cure. Meet IAMA Therapeutics S.r.l. @ #Sachs_BEF More Info @ https://lnkd.in/d7zEuKym #BigPharma #Dealmakers #PharmaIndustry #BiotechInEuropeForum #LifeSciences #Biotech #BioPharma #Partnering #Investment #Startups #Oncology #Neurology #Genomics #Immunotherapy #CNS #Autoimmune #Cardiovascular #BiotechIndustry #BioTechInvestment #Innovation #InvestmentForum #BiotechConference #EuropeanBiotech #SachsAutumnLifeSciencesWeek #SALSW

🔥 Unlock Tumor Microenvironment Insights at Immunotherapies Xchange Maryland 2024 🔥 We’re thrilled to announce that Dr. Rimas Orentas, Scientific Director at Caring Cross, will lead a key roundtable discussion at Immunotherapies Xchange Maryland 2024! 🧬✨ Session Highlight: 🗓 Date: October 29, 2024 ⏰ Time: 09:05 AM - 10:05 AM 🔍 Focus: Investigating how tumor microenvironment supports immune evasion Join us to explore: 🌟 How targeting the tumor microenvironment can open new drug development avenues. 🧠 Insights from the transient activity of immunotherapy in CNS tumors. 📊 Discovery platforms and datasets that offer the best leads for overcoming negative tumor microenvironments. 🔬 How new immunotherapies can build on the successes of immune checkpoint blockade. Dr. Orentas brings extensive expertise from leading impactful research in CAR-T therapies and cell-based treatments. Don’t miss this opportunity to gain valuable insights and network with top industry professionals! 🚀 📍 Location: College Park Marriott Hotel, Maryland 🔗 Register now: https://lnkd.in/ehzkCKpy Only available for Senior Scientists and above, from Bio and Pharma companies, with a drug pipeline. 💊 #Immunotherapies #ClinicalDevelopment #CancerResearch #TumorMicroenvironment #DrugDevelopment #ImmunotherapiesResearch #CARtherapy #CellTherapies #Oncology #BiomedicalInnovation #ResearchInsights #Pharma #Biotech #CNSImmunotherapies #CheckpointBlockade #FutureOfMedicine #MedicalResearch #HealthTech #ScientificAdvancements #BiotechNetworking #PharmaEvents #InnovationInMedicine #ResearchAndDevelopment #ImmunotherapiesXchange #hubxchange #Xchanges #Roundtable #FreePass #RegisterNow #ComplimentaryPass